share_log

VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders

VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders

VERU ALERT:在代表Veru Inc.股东提起的集体诉讼中,克莱因律师事务所宣布首席原告的最后期限为2023年2月6日
PR Newswire ·  2023/01/17 06:00

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company violated federal securities laws.

纽约2023年1月17日 /PRNewswire/ — 克莱因律师事务所宣布,已代表Veru Inc.(纳斯达克股票代码:VERU)的股东提起集体诉讼,指控该公司违反了联邦证券法。

This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline: February 6, 2023
No obligation or cost to you.

该诉讼是代表所有在两者之间购买或以其他方式收购Veru Inc.普通股的投资者提起的 2022年5月11日2022年11月9日,包括。
首席原告截止日期: 2023年2月6日
您无需承担任何义务或费用。

Learn more about your recoverable losses in VERU:

详细了解您在 VERU 中可追回的损失:

Veru Inc. NEWS - VERU NEWS

Veru Inc. 新闻-VERU 新闻

CLASS ACTION CASE DETAILS: The filed complaint alleges that Veru Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.

集体诉讼案件详情: 提起的申诉称,Veru Inc. 做出了重大虚假和/或误导性陈述和/或未能披露:1) 该公司隐瞒了有关sabizabulin第三阶段试验数据以及公司与美国食品药品监督管理局互动的重大不利事实;2) 被告误导了Veru的股东,使他们认为sabizabulin第三阶段试验的数据足以支持紧急使用授权(“EUA”),甚至在不进行任何进一步研究的情况下提交新药申请;以及 3)该公司的文件掩盖了Veru在获得其EUA请求批准时面临的真正风险。

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Veru you have until February 6, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

作为股东,这对你意味着什么: 如果你在 Veru 中遭受了损失,你必须等到 2023年2月6日 向法院申请首席原告身份。您无需担任首席原告即可分担任何追回款项。

NO COST TO YOU: If you purchased Veru securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

对你来说不用花钱:如果您在相关时期内购买了Veru证券,则可能有权获得赔偿,无需支付任何自付费用。

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the VERU lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:

如何保护你的经济利益: 有关 VERU 诉讼的更多信息,请致电 212-616-4899 与 J. Klein, Esq. 联系或点击以下链接:

ABOUT KLEIN LAW FIRM
关于克莱因律师事务所

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

J. Klein, Esq. 代表投资者参与涉及全国金融欺诈的证券诉讼。克莱因律师事务所是一家精品诉讼事务所,在证券法、公司融资和商业诉讼等广泛领域拥有经验。自2011年以来,我们经验丰富的律师以个性化为重点,为客户取得了卓越的成绩。律师广告。先前的结果并不能保证类似的结果。

CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899

联系人:
J. Klein,Esq
第五大道 535 号
四楼
纽约市,纽约 10017
[电子邮件保护]
电话:(212) 616-4899

SOURCE The Klein Law Firm

来源:克莱因律师事务所

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发